1. A compound of Formula I:
wherein
Z1 and Z2 are each independently CH or N;
R1 is H or optionally substituted hydroxy, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R2 and R2\u2032 are each independently H or optionally substituted alkyl, cycloalkyl, or heterocycloalkyl, or when R2\u2032 is H then R2 and R1 can together form an aziridine or azetidine ring;
R3 and R4 are each independently H or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or, R3 and R4 are each carbon and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
R5 and R6 are each independently H or optionally substituted hydroxy, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or R5 and R6 are each carbon and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
M is a bond, optionally substituted alkylene group of 1 to 5 carbon atoms, optionally substituted with a lower alkyl; or M and G together form a bond;
G is a bond, a heteroatom, \u2014S(O)n\u2014, \u2014NR8\u2014, \u2014NCOR8\u2014, or \u2014NS(O)nR8\u2014, where R8 is selected from the group consisting of lower alkyl, optionally-substituted lower alkyl and C3-8 cycloalkyl; or M and G together form a bond;
R7 is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, each substituted with -L1-R10 and each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally further substituted;
L1 is a covalent bond or C1-6 alkylene, alkenylene, or alkynylene;
R10 is an optionally substituted 5-, 6-, or 7-membered heterocycloalkyl with at least one N or O atom in the ring or R10 is heteroaryl with at least one N atom in the ring;
each n can be the same or different and is 0, 1, or 2;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein when Z1 is N and Z2 is CH, then at least one of the following is true:
(i) R5 and R6 together are not both carbon atoms linked by a single covalent bond;
(ii) R5 and R6 are both carbon atoms linked by a single covalent bond and R5 is disubstituted;
(iii) R5 and R6 are both carbon atoms linked by a single covalent bond and R6 is mono- or disubstituted;
(iv) R5 and R6 are both carbon atoms linked by a single covalent bond and R3 and R4 are both carbon atoms linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein
M is optionally-substituted C1-C5 alkylene, optionally substituted with a lower alkyl;
G is a bond;
R7 is aryl or heteroaryl, each substituted with -L1-R10 and each aryl or heteroaryl is optionally further substituted;
L1 is a covalent bond or C1-C4 alkylene, alkenylene, or alkynylene;
R10 is a tetrahydrofuranyl or tetrahydropyranyl moiety each of which is optionally substituted with hydroxy, lower alkyl, lower alkoxy, or optionally-substituted lower alkoxy selected from the group consisting of arylalkyloxy, alkylcarbonyloxy, arylcarbonyloxy, and acetyloxy; or, R10 is an optionally-substituted nitrogen-containing 5- to 7-membered heteroaryl or heterocycloalkyl group and (i) R3 and R4 are covalently linked, (ii) R5 and R6 are covalently linked or (iii) both R3 and R4 are covalently linked, and R5 and R6 are covalently linked.
4. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein
M is C1-C3 alkylene, but not alkenylene or alkynylene, optionally-substituted with lower alkyl;
L1 is a single covalent bond;
R10 is tetrahydrofuranyl or tetrahydropyranyl substituted with at least one hydroxy or acetyloxy group.
5. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein
M is C1-C3 alkylene, but not alkenylene or alkynylene, optionally-substituted with lower alkyl;
L1 is a single covalent bond;
R10 is a 5- to 7-membered heteroaryl or heterocycloalkyl group having a single nitrogen atom in the ring and no additional heteroatoms.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R1 is H, methyl, allyl, propargyl, ethyl, cycloalkyl, hydroxyethyl or cyclo alkylmethyl.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R2 and R2\u2032 are independently H, methyl, fluoromethyl, difluoromethyl, ethyl, hydroxyethyl, fluoroethyl, and cycloalkyl.
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R3 and R4 are independently H, methyl, ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally-substituted with hydroxyl, mercapto, sulfonyl, alkylsulfonyl, halogen, pseudohalogen, amino, carboxyl, alkyl, haloalky, pseudohaloalkyl, alkoxy, or alkylthio, or R3 and R4 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O.
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R5 and R6 are independently optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R5 and R6 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O.
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein
R1 is H, methyl, allyl, propargyl, ethyl, cycloalkyl, hydroxyethyl or cycloalkylmethyl;
R2 and R2\u2032 are independently H, methyl, fluoromethyl, difluoromethyl, ethyl, hydroxyethyl, fluoroethyl, and cycloalkyl;
R3 and R4 are independently optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R3 and R4 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O;
R5 and R6 are independently optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R5 and R6 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O;
M is C1-C3 alkylene optionally-substituted with lower alkyl.
11. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein
R1 is H, methyl, allyl, propargyl, ethyl, cycloalkyl, hydroxyethyl or cycloalkylmethyl;
R2 and R2\u2032 are independently H, methyl, fluoromethyl, difluoromethyl, ethyl, hydroxyethyl, fluoroethyl, and cycloalkyl;
R3 and R4 are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O;
R5 and R6 are independently H or optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R5 and R6 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
M is C1-C3 alkylene optionally-substituted with lower alkyl.
12. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein
R7 is IIa or IIb:
L1 is a single covalent bond
X is \u2014N\u2014, \u2014C\u2550C(R16)\u2014, \u2014N\u2550C\u2014 or \u2014C(O)N\u2014;
Y is \u2014C\u2014, \u2014N\u2014, or \u2014N+\u2014; such that,
When Y is \u2014C\u2014 then R9, R11, R12, R13, R14, R15, and R16 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime; provided that when X is \u2014N\u2014 or \u2014C(O)\u2014N\u2014, -L1-R10 is bound to the \u2014N\u2014 atom; and, when X is \u2014C\u2550C(R16)\u2014 or \u2014N\u2550C\u2014, -L1-R10 is bound to the \u2014C\u2550 atom; and
When Y is \u2014N\u2014 or \u2014N+\u2014, then R11 is absent or \u2014O\u2212, and R9, R12, R13, R14, R15, and R16 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime; provided that when X is \u2014N\u2014 or \u2014C(O)\u2014N\u2014, -L1-R10 is bound to the \u2014N\u2014 atom; and, when X is \u2014C\u2550C(R16)\u2014 or \u2014N\u2550C\u2014, -L1-R10 is bound to the \u2014C\u2550 atom.
13. The compound of claim 1 or a pharmaceutically acceptable salt thereof having the formula (III):
wherein
Y is \u2014C\u2014, \u2014N\u2014, or \u2014N+\u2014; such that,
A is a single or double bond;
When A is a single bond and Y is \u2014C\u2014 then R9a, R9b, R11, R12, R13, R14, and R17 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime;
When A is a single bond and Y is \u2014N\u2014 or \u2014N+\u2014, then R11 is absent or \u2014O\u2212, and R9a, R9b, R12, R13, R14, and R17 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime;
When A is a double bond and Y is \u2014C\u2014 then R9b and R17 are absent; and R9a, R11, R12, R13, and R14 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime;
When A is a double bond and Y is \u2014N\u2014 or \u2014N+\u2014, then R9b and R17 are absent; and R11 is absent or \u2014O\u2212, and R9a, R12, R13, and R14 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, or carboxylate, sulfonate, sulfone, imine, or oxime.
14. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein
R7 is IIa or IIb;
X is \u2014N\u2014;
Y is \u2014C\u2014, \u2014N\u2014, or \u2014N+\u2014; such that
When Y is \u2014C\u2014, then R9, R11, R12, R13, R14 and R15 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy or heteroaryloxy;
When Y is \u2014N\u2014, then R11 is absent, and R9, R12, R13, R14 and R15 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy or heteroaryloxy;
When Y is \u2014N+\u2014, then R11 is \u2014O\u2212, and R9, R12, R13, R14 and R15 are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy or heteroaryloxy;
R3 is methyl, ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally-substituted with hydroxyl, mercapto, halogen, pseudohalogen, amino, carboxyl, alkyl, haloalkyl, pseudohaloalkyl, alkoxy, or alkylthio;
R2 is \u2014H, methyl, fluoromethyl, difluoromethyl, ethyl, fluoroethyl, and cycloalkyl;
R2\u2032 is H;
R1 is selected from H, methyl, allyl, propargyl, ethyl, cycloalkyl, or cycloalkylmethyl;
Z1 is nitrogen;
Z2 is \u2014CH\u2014;
R4 is \u2014H and R5 and R6 are both carbon atoms and together form C2-C4 alkylene; or, R3 and R4 are both carbon atoms and together form C2-C4 alkylene; or, both R5 and R6 together and R3 and R4 together both form C2-C4 alkylene groups;
L1 is a covalent bond.
15. The compound of claim 14 or a pharmaceutically acceptable salt thereof wherein
R9, R11, R12, R13, R14 and R15 are, independently, \u2014H, -halogen, or optionally-substituted lower alkyl;
R3 is optionally-substituted lower alkyl, C3-C8 cycloalkyl, or heterocycloalkyl wherein the optional substituents are hydroxy, lower alkoxy, or lower alkyl;
R2 is optionally-substituted lower alkyl, C3-C8 cycloalkyl, or heterocycloalkyl wherein the optional substituents are hydroxy, lower alkoxy, or lower alkyl;
R2\u2032 is H;
R1 is \u2014H or lower alkyl;
R5 and R6 are both carbon atoms and are linked by a covalent bond;
R4 is \u2014H;
Z2 is \u2014CH\u2014;
R10 is tetrahydropyran, tetrahydrofuran, D- or L-fucose, D- or L-xylose, D- or L-galactose, or D- or L-glucose, pyrrolidine, piperidine, perhydroazapine, pyridine, pyrimidine, or pyrazine.
16. The compound of claim 1 selected from the group consisting of Compounds A through U and Compounds HH through SS, as follows, or a pharmaceutically acceptable salt thereof:
Com-
pound
R1
R2
R3
R18
R9
R13
R12
R11
R10
A
Me
Me
tBu
H
4-F-
H
F
H
D-xylose
phenyl
B
Me
Me
iPr
H
4-F-
H
F
H
D-xylose
phenyl
C
Me
Me
tBu
H
4-F-
H
F
Me
L-fucose
phenyl
D
Me
Me
iPr
H
H
H
H
Me
L-fucose
E
Me
Me
iPr
H
H
H
H
H
D-xylose
F
Me
Me
tBu
H
H
H
F
H
L-fucose
G
Me
Me
cHex
H
H
H
F
H
L-fucose
H
Me
Me
iPr
H
H
H
F
H
L-fucose
I
Me
Me
iPr
H
H
H
F
H
D-xylose
J
Me
Me
iPr
H
H
H
F
H
D-
glucose
K
Me
Me
iPr
H
H
H
F
H
D-
galactose
L
Me
Me
iPr
H
H
H
F
H
D-
galactose
tetra
acetate
M
Me
Me
cHex
H
H
H
F
H
D-xylose
N
Me
Me
tBu
H
H
H
F
H
D-xylose
O
Me
Me
R-(Me)
H
4-F-
H
F
H
L-fucose
CHOMe
phenyl
P
Me
Me
R-(Me)
S-
4-F-
Me
H
H
L-fucose
CHOMe
OH
phenyl
Q
Me
Me
tert-
S-
4-F-
Me
H
H
L-fucose
Butyl
OH
phenyl
R
Me
Me
R-(Me)
H
4-F-
Me
H
H
L-fucose
CHOMe
phenyl
S
Me
Me
tert-
H
4-F-
Me
H
H
L-fucose
Butyl
phenyl
T
Me
Me
tert-
S-
4-F-
H
F
H
L-fucose
Butyl
OH
phenyl
U
Me
Me
R-(Me)
S-
4-F-
H
F
H
L-fucose
CHOMe
OH
phenyl
Compound
R1
R2
R3
R18
HH
Me
Me
tBu
H
II
Me
Me
R-(Me)CHOMe
H
JJ
Me
Et
R-(Me)CHOMe
H
KK
Me
cyclo-propyl
R-(Me)CHOMe
H
LL
Me
Me
tBu
S-OH
MM
Et
Me
tBu
S-OH
NN
Me
CH2OH
tBu
S-OH
OO
Me
cyclo-propyl
tBu
S-OH
PP
Me
Me
R-(Me)CHOMe
S-OH
QQ
Et
Me
R-(Me)CHOMe
S-OH
RR
Me
Et
R-(Me)CHOMe
S-OH
SS
Me
cyclo-propyl
R-(Me)CHOMe
S-OH.
17. A compound having Formula IV, or a pharmaceutically acceptable salt thereof:
wherein
Z1a, Z2a, Z1b, and Z2b are independently CH or N;
R1a and R1b are independently H or optionally substituted hydroxyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and when R2a\u2032 is H then R2a and R1a can together form an aziridine or azetidine ring and when R2b\u2032 is H then R2b and R1b can together form an aziridine or azetidine ring;
R2a, and R2b are independently H or optionally substituted alkyl, cycloalkyl, or heterocycloalkyl; or when R2a\u2032 is H then R2a and R1a can together form an aziridine or azetidine ring and when R2b\u2032 is H then R2b and R1b can together form an aziridine or azetidine ring;
R3a, R3b, R4a and R4b are independently H or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or, R4a and R3a, or R4b and R3b, or both, are carbon atoms linked by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
R5a, R6a, R5b, and R6b are independently H or optionally substituted hydroxyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or R5a and R6a or R5b and R6b, or both, are carbon atoms linked by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
n can be the same or different in each usage and is 0, 1, or 2;
Xa is \u2014O\u2014, \u2014N(La\u2014R10a)\u2014, \u2014S\u2014, optionally-substituted \u2014C(La\u2014R10a)=CH\u2014, \u2014C(O)\u2014O\u2014, \u2014C(O)\u2014N(La\u2014R10a)\u2014, \u2014N\u2550C(La\u2014R10a)-;
Xb is \u2014O\u2014, \u2014N(Lb-R10b)\u2014, \u2014S\u2014, optionally-substituted \u2014C(Lb-R10b)=CH\u2014, \u2014C(O)\u2014O\u2014, \u2014C(O)\u2014N(Lb-R10b)\u2014, \u2014N\u2550C(Lb-R10b)-, provided that if Xb is \u2014O\u2014, \u2014S\u2014, or \u2014C(O)\u2014O\u2014, then Xa is \u2014N(La\u2014R10a)\u2014, optionally-substituted \u2014C(La\u2014R10a)=CH\u2014, \u2014C(O)\u2014N(La\u2014R10a)\u2014, or \u2014N\u2550C(La\u2014R10a)-, and if Xa is \u2014O\u2014, \u2014S\u2014, or \u2014C(O)\u2014O\u2014, then Xb is \u2014N(Lb-R10b)\u2014, optionally-substituted \u2014C(Lb-R10b)=CH\u2014, \u2014C(O)\u2014N(Lb-R10b)\u2014, or \u2014N\u2550C(Lb-R10b)-;
La and Lb are independently a covalent bond or C1-C4 alkylene, alkenylene, or alkynylene;
R10a and R10b are independently an optionally substituted 5-, 6-, or 7-membered heterocycloalkyl with at least one N or O atom in the ring or heteroaryl with at least one N atom in the ring provided that one but not both of R10a and R10b can be \u2014H or absent;
Wa and Wb are together a Linker and
Ya and Yb are independently \u2014C\u2014, \u2014N\u2014, or \u2014N+-; such that,
(a) when Ya or Yb is \u2014C\u2014 then R11a, R11b, R12a, R12b, R13a, R13b, R14a and R14b respectively are independently \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime;
(b) when Ya or Yb is \u2014N\u2014 then R11a, and R11b respectively are absent, and R12a, R12b, R13a, R13b, R14a and R14b respectively are independently \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime and
(c) when Ya or Yb is \u2014N+-, then R11a and R11b respectively are \u2014O\u2212 and R12a, R12b, R13a, R13b, R14a, and R14b are, independently, \u2014H, halogen, or optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkoxyalkyl, sulfonate, aryloxy, heteroaryloxy, acyl, acetyl, carboxylate, sulfonate, sulfone, imine, or oxime.
18. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein when Z1a is N and Z2a is CH, and Z1b is N and Z2b is CH, then at least one of the following is true:
(i) R5a and R6a are not both carbon atoms linked by a single covalent bond;
(ii) R5a and R6a are both carbon atoms linked by a single covalent bond and R6a is disubstituted;
(iii) R5a and R6a are both carbon atoms linked by a single covalent bond and R6a is mono- or disubstituted;
(iv) R5a and R6a are both carbon atoms linked by a single covalent bond and R3a and R4a are both carbon atoms linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O;
(v) R5a and R6a are both carbon atoms linked by a single covalent bond and R2a is not H.
19. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein R3a, R4a, R3b, and R4b are independently selected from H, methyl, ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally-substituted with hydroxyl, mercapto, sulfonyl, alkylsulfonyl, halogen, pseudohalogen, amino, carboxyl, alkyl, haloalky, pseudohaloalkyl, alkoxy, or alkylthio.
20. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein R2a and R2b are independently selected from \u2014H, methyl, fluoromethyl, difluoromethyl, ethyl, fluoroethyl, hydroxyethyl, and cycloalkyl.
21. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein R1a and R1b are independently selected from H, methyl, allyl, propargyl, ethyl, hydroxyethyl, cycloalkyl, or cycloalkylmethyl.
22. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein R3a, R4a, R3b, and R4b are independently optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy.
23. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein Z1a and Z1b are both N and Z2a and Z2b are both C and wherein R5a and R6a, and R5b and R6b, are each carbon and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O.
24. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein Z1a and Z1b are both N and Z2a and Z2b are both C and wherein R3a and R4a, and R3b and R4b, are each carbon and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 8 carbon atoms where one to three carbon atoms can be replaced by N, O, S(O)n, or C\u2550O.
25. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein Wa and Wb together are a covalent bond or optionally substituted alkylene, cycloalkyl, or aryl, of 2 to 20 carbon atoms where one or more carbon atoms can be replaced with N, O, or S(O)n; and Xa and Xb are independently \u2014O\u2014, \u2014S\u2014, or \u2014C(O)\u2014O\u2014.
26. The compound of claim 17 or a pharmaceutically acceptable salt thereof wherein one of R10a and R10b is \u2014H or is absent.
27. A compound selected from the group consisting of Compounds V through Z and AA through GG, as follows, or a pharmaceutically acceptable salt thereof:
Compound
R1
R2
R3
R18
R13
R12
R10
V
Me
Me
iPr
H
H
F
L-fucose
W
H
H
iPr
H
H
F
L-fucose
X
H
H
iPr
H
H
F
D-xylose
Y
Me
Me
iPr
H
H
F
D-xylose
Z
Me
Me
R-(Me)CHOMe
H
F
H
D-galactose
AA
Me
Me
iPr
H
F
H
D-galactose
BB
Me
Me
R-(Me)CHOMe
H
F
H
D-glucose
CC
Me
Me
iPr
H
F
H
D-glucose
DD
Me
Me
iPr
H
F
H
L-fucose
EE
Me
Me
R-(Me)CHOMe
H
H
F
L-fucose
FF
Me
Me
R-(Me)CHOMe
S-OH
H
F
L-fucose
GG
Me
Me
R-(Me)CHOMe
S-OH
H
F
L-fucose.
28. The compound of claim 1 or a pharmaceutically acceptable salt thereof having the formula
wherein R1, R2, and R3 are independently lower alkyl, lower alkoxy, lower alkanol, or C3-C6 cycloalkyl; R18 is H or OH; R9 is H or phenyl optionally substituted with halogen; R11, R12, and R13 are independently H or halogen and R10 is an optionally substituted 5-, 6-, or 7-membered heterocycloalkyl with at least one N or O atom in the ring or R10 is heteroaryl with at least one N atom in the ring.
29. The compound of claim 17 or a pharmaceutically acceptable salt thereof having the formula
wherein R1, R2, and R3 are independently lower alkyl, lower alkoxy, lower alkanol, or C3-C6 cycloalkyl; R18 is H or OH; R11, R12, and R13 are independently H or halogen and R10 is an optionally substituted 5-, 6-, or 7-membered heterocycloalkyl with at least one N or O atom in the ring or R10 is heteroaryl with at least one N atom in the ring.
30. A method for inducing apoptosis in a cell comprising contacting the cell with a compound of claim 1 in an amount sufficient to induce apoptosis in the cell.
31. The method of claim 30, wherein said cell is neoplastic.
32. The method of claim 30, wherein said cell overexpresses an inhibitor of caspase.
33. The method of claim 32, wherein the inhibitor inhibits activation or activity of one or more of a caspase selected from caspase-3, caspase-7 and caspase-9.
34. A method of stimulating apoptosis in a cell comprising contacting the cell with a compound of claim 1 in an amount sufficient to stimulate apoptosis in the cell.
35. The method of claim 34, wherein said cell is a cancer cell.
36. A method of enhancing apoptosis of pathogenic cells in vivo in an individual comprising administering to the individual a therapeutically effective amount of a compound of claim 1.
37. The method of claim 36 further comprising administering a second therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy and combinations thereof.
38. A pharmaceutical composition comprising: a compound selected from a compound of claim 1 and a pharmaceutically acceptable excipient.
39. The composition of claim 38 further comprising a second chemotherapeutic agent.
40. The composition of claim 39, wherein said second chemotherapeutic agent is selected from altretamine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphomide, dacarbazine, hexamethylmelamine, ifosfamide, lomustine, melphalan, mechlorethamine, oxaliplatin, procarbazine, streptozocin, temozolomide, thiotepa, uramustine, docetaxel, etoposide, irinotecan, paclitaxel, tenisopide, topotecan, vincristine, vinblastine, vindesine, vinorelbine, bleomycin, dactinomycin, daunorubicin, epirubicin, hydroxyurea, idarubicin, mitomycin, mitoxantrone, plicamycin, azathioprine, capecitabine, cladribine, cytarabine, fludarabine, fluorouracil, floxuridine, gemcitabine, mercaptopurine, methotrexate, nelarabine, pemeterxed, pentostatin, thioguanine, camptothecan, irinotecan, topotecan, BNP 1350, SN 38,9-amino-camptothecan, lurtotecan, gimatecan, diflomotecan, an anthracycline, anthraquinone, podophyllotoxin, doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, loxoxantrone, etoposide, teniposide and combinations thereof.
41. The composition of claim 39, wherein said second chemotherapeutic agent is selected from alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors and combinations thereof.
42. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein
R1 is H, methyl, allyl, propargyl, ethyl, cycloalkyl, hydroxyethyl or cycloalkylmethyl;
R2 and R2\u2032 are independently H, methyl, fluoromethyl, difluoromethyl, ethyl, hydroxyethyl, fluoroethyl, and cycloalkyl;
R3 and R4 are independently optionally substituted lower alkyl or C3-C8 cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R3 and R4 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O;
R5 and R6 are independently optionally substituted lower alkyl or C3-Cs cycloalkyl wherein the optional substituents are hydroxy or lower alkoxy, or R5 and R6 are carbon atoms and are linked by a covalent bond or by an optionally-substituted alkylene or alkenylene group of 1 to 3 carbon atoms of which 1 or more atoms can be replaced by N, O, S(O)n, or C\u2550O;
M is C1-C3 alkylene optionally-substituted with lower alkyl.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A sheet storage apparatus for storing a sheet conveyed by a sheet conveyance unit, comprising:
a plurality of sheet storage units vertically stacked at a plurality of stages;
a lower guide disposed in each of the plurality of sheet storage units and configured to guide a lower surface of the conveyed sheet;
an upper guide disposed in each of the plurality of sheet storage units and configured to guide an upper surface of the conveyed sheet;
a rotary member disposed in each of the plurality of sheet storage units and in one of the lower guide and the upper guide, and configured to be rotatable by contacting a sheet stored in a sheet storage unit from a home position around a rotational axis extending in a direction orthogonal to a sheet conveying direction;
a sensor disposed in each of the plurality of sheet storage units and configured to output a signal according to a position of the rotary member; and
a control unit configured to detect presence of a sheet in the sheet storage unit according to an output of the sensor,
wherein at the home position, at least a part of the rotary member overlaps a rotational axis of a rotary member of an adjacent sheet storage unit in a vertical direction.
2. The sheet storage apparatus according to claim 1,
wherein at least one of the lower guide and the upper guide includes a notch into which the rotary member of the adjacent sheet storage unit is able to enter.
3. The sheet storage apparatus according to claim 1, wherein the rotary member is tapered from the rotational axis of the rotary member toward a protruded portion of the rotary member.
4. The sheet storage apparatus according to claim 1, wherein in a direction of the rotational axis, lengths of the rotary member and the notch are different from those of another rotary member, and lengths of the adjacent rotary member and the notch are gradually lager.
5. The sheet storage apparatus according to claim 1, further comprising an extrusion unit configured to extrude at least a part of the sheet stored in the sheet storage unit out of the sheet storage unit.
6. The sheet storage apparatus according to claim 1, wherein the rotary member includes a bent wire member, and at the home position, the wire member overlaps the other of the lower guide and the upper guide in the vertical direction.
7. A sheet storage apparatus for storing a sheet conveyed by a sheet conveyance unit, comprising:
a plurality of sheet storage units,
wherein each of the plurality of the sheet storage units includes:
a first guide having a stacking surface of the conveyed sheet;
a second guide facing the first guide;
a moving member protruding from one of the first guide and the second guide to the other and configured to move by contacting a sheet stored in the sheet storage unit from a contact position; and
a sensor configured to detect the sheet in the sheet storage unit according to a movement of the moving member; and
wherein at the contact position, at least a part of the moving member overlaps at least a part of the other of the first guide and the second guide in a vertical direction.
8. The sheet storage apparatus according to claim 7, wherein the moving member is rotatable from the contact position.
9. The sheet storage apparatus according to claim 8, wherein at the contact position, at least a part of the moving member overlaps at least a part of a rotational axis of the moving member of an adjacent sheet storage unit.
10. The sheet storage apparatus according to claim 7, wherein the moving member includes a bent wire member.
11. The sheet storage apparatus according to claim 7, wherein the plurality of sheet storage units are vertically stacked.
12. The sheet storage apparatus according to claim 7, further comprising a control unit configured to determine whether a sheet is stored in each of the plurality of sheet storage units.
13. The sheet storage apparatus according to claim 7, wherein each of the sheet storage unit includes an extrusion unit configured to extrude at least a part of the sheet stored in the sheet storage unit out of the sheet storage unit.
14. An image forming apparatus comprising:
an image forming unit configured to form an image on a sheet; and
the sheet storage apparatus according to claim 7,
wherein each of the plurality of sheet storage units stores a sheet on which an image has been formed by the image forming unit.